Ma-Spore ALL 2020 Study

The primary objective of this trial is to improve the overall survival rate of children and young adult with B-lineage acute lymphoblastic leukemia (B-ALL) in Singapore and Malaysia in the context of a multicenter cooperative trial using a risk-stratified therapy.

Trial Details

NCT ID

NCT06336395

Phase

PHASE2

Sponsor

National University Hospital, Singapore

Status

RECRUITING

Cancer Type

Acute Lymphoblastic (ALL) Leukemia

Interventions

Prednisolone
Dexamethasone
Vincristine
Methotrexate
L-Asparaginase
Pegylated asparaginase

Locations (sample)

Kuala Lumpur, Malaysia|3.1412,101.68653
Kuala Lumpur, Malaysia|3.1412,101.68653
Singapore, Singapore|1.28967,103.85007

Key Eligibility Criteria

Has been diagnosed with B-lineage ALL as evidenced by:
BMA blasts \> 20% AND
Leukemic process in the bone marrow, peripheral blood or any extra medullary tissue with confirmation of B-lymphoid differentiation by flow immunop…
Age \< 41 years of age at enrolment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →